Clinical Trial Update: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL [Phase 1]

View source ↗

Summary

A Phase 1 study of ThisCART19A in relapsed/refractory B-cell acute lymphoblastic leukemia has completed, reporting on safety, efficacy, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• ThisCART19A (ThisCART19A)

Snippet

Sponsor: Zhejiang University | Conditions: B-ALL | Phase 1 | Status: COMPLETED